Anti-obesity drug benefits 'no longer outweigh risks'

Acomplia's European marketing authorisation for obese and overweight people has been suspended by the European Medicines Agency (EMEA).

The EMEA said it has decided that the benefits of rimonabant, which is marketed in Europe as Acomplia, no longer outweigh its risks. Prescribers should not issue any prescriptions for Acomplia and should review the treatment of patients currently taking the medicine, the EMEA said.

There is no need for patients to stop treatment with Acomplia immediately, but patients who wish to stop can do so at any time, the EMEA advised. Patients who are currently taking Acomplia should consult their doctor or pharmacist at a convenient time to discuss their treatment.

Acomplia's manufacturer Sanofi-Aventis said that it was complying with the EMEA’s recommendation.

‘Sanofi-Aventis is committed to provide additional evidence for the re-evaluation of the benefit/risk profile of Acomplia in patients with diabetes and cardiovascular disease through the ongoing clinical studies,’ the company said in a statement.

‘Sanofi-Aventis remains committed to Acomplia to bring an important therapeutic approach to obese and overweight patients.’

The EMEA said it had assessed the benefits and risks of Acomplia, including data from studies completed since the drug was licensed. These showed an increased risk of psychiatric disorders patients taking Acomplia.

The EMEA said it believed that these side effects could not be adequately addressed by risk minimisation measures.

In addition, the agency said that the effectiveness of Acomplia in clinical practice had been found to be more limited than was expected on the basis of the clinical trials because available data indicate that patients generally take Acomplia
only for a short period.

tom.moberly@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Most children could be removed from shielded patient list, deputy CMO suggests

Most children could be removed from shielded patient list, deputy CMO suggests

Most children could be removed from the shielded patient list in a future wave of...

GPs can provide some care for shielded patients in clinical settings, NHS England confirms

GPs can provide some care for shielded patients in clinical settings, NHS England confirms

GPs can provide care to shielded patients in 'infection-controlled clinical settings'...

How digital assistants can help patients manage their health and wellbeing

How digital assistants can help patients manage their health and wellbeing

A project in Staffordshire has shown how practices can make use of digital technology...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

Fair death-in-service deal for locums vital before second COVID-19 wave, warns BMA

Fair death-in-service deal for locums vital before second COVID-19 wave, warns BMA

The government must do ‘the right thing’ and secure adequate death-in-service benefits...

GP workload fears over antibody testing rollout for 'no clinical benefit'

GP workload fears over antibody testing rollout for 'no clinical benefit'

GP practices are being contacted by patients asking for antibody tests as the government...